about
Association between KRAS mutation and lung metastasis in advanced colorectal cancer.Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysisRefractory carcinoid syndrome: a review of treatment options.The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials.Clinical utility of circulating cell-free DNA in advanced colorectal cancer.Genomic landscape of cell-free DNA in patients with colorectal cancer.Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future PerspectivesValue of Systemic Staging in Asymptomatic Early Breast CancerPatterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapyPrognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic CharacteristicsEfficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDevelopment of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
P50
Q35677827-088B1E70-5356-4F58-A778-1D4B2FDAF2E7Q37213101-9092F096-781B-4905-979F-35804036899BQ37573426-18FFFD2D-3E04-40C5-8B17-5A5955C6AD79Q37632161-BDB321B7-40C4-43C6-AE33-8F6F25280B00Q38487996-8057C7F4-55E8-48FE-8F2E-3F8984586F9AQ41545171-5DDD47DE-7F0F-40D7-AC07-5D7C4DD13134Q46334692-86790B73-DECE-4D10-8B87-5A595C1E7D2EQ47337203-6E7973A7-2589-4528-BA9B-63AFCABC4493Q49586760-7283DE59-989C-47C9-9B3D-23E5326E4711Q52568022-E3FEB438-4436-4E50-85F4-8871E8391A26Q64243451-5705E9B5-A312-4621-8B5C-E2878AF7E90CQ89501718-BD9CBB06-775B-4B7E-850E-2537F9F1B687Q90376518-E0D16D92-C52B-4715-AF6C-D799367554B2Q91391239-8CC1456D-1039-4430-B2DC-473E2AD460D5Q91629321-89F73232-55AB-482E-817B-1F007B5C5E49Q92241725-244ED632-15DE-463B-B8B9-760CD9CF5EE5Q93270142-B0CEDB40-E190-4AD0-857B-A300ABC3F8E9
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Allan A L Pereira
@en
Allan A L Pereira
@nl
type
label
Allan A L Pereira
@en
Allan A L Pereira
@nl
prefLabel
Allan A L Pereira
@en
Allan A L Pereira
@nl
P31
P496
0000-0002-8573-7364